Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrimidines
  • Pyrroles
  • Quality of Life
  • Sulfonamides

abstract

  • Patients randomized to pazopanib had a slightly longer Q-TWiST in comparison with sunitinib patients, and this was primarily due to the reduced length of TOX.

publication date

  • April 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4996632

Digital Object Identifier (DOI)

  • 10.1002/cncr.29888

PubMed ID

  • 27000445

Additional Document Info

start page

  • 1108

end page

  • 15

volume

  • 122

number

  • 7